---
schema_version: "secwatch.filing_event.v1"
accession: "0000883984-24-000040"
form_type: "8-K"
ticker: "ICUI"
cik: "0000883984"
company_name: "ICU MEDICAL INC/DE"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:33:52.664166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ICU Medical Q3 2024 revenue up 6.5% to $589.1M; GAAP net loss $33M, adj EPS $1.59

## Summary
- Revenue $589.1M vs $553.3M YoY; GAAP gross margin improved to 34.8% from 33.2%.
- GAAP net loss $(33.0)M ($1.35 per diluted share) vs net income $7.2M ($0.30) in Q3 2023.
- Adjusted diluted EPS $1.59 vs $1.57 YoY; Adjusted EBITDA $94.8M vs $89.8M.
- Company updated FY2024 guidance; specific guidance numbers not fully disclosed in excerpt.

## SEC filing metadata
- accession: 0000883984-24-000040
- form_type: 8-K
- ticker: ICUI
- cik: 0000883984
- company_name: ICU MEDICAL INC/DE
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883984/000088398424000040/0000883984-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883984/000088398424000040/icui-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000883984-24-000040
- JSON: https://secwatch.observer/filing/0000883984-24-000040.json
- Plain text: https://secwatch.observer/filing/0000883984-24-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.